Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
暂无分享,去创建一个
L. Campbell | J. Szer | I. Lewis | P. Marlton | A. Roberts | A. Wei | C. Tiley | A. Schwarer | D. Gill | J. Seymour | J. di Iulio | P. Rowlings | J. Moore | U. Hahn | A. Grigg | K. Bradstock | M. Hertzberg | A. Enno | R. Lowenthal | J. D’Rozario | M. Leahy | P. Bardy | I. Cunningham | E. Link | L. Coyle | P. Cannell | W. Benson | G. Cull | A. Mills | P. Campbell | J. Taper | S. Deveridge | K. Cartwright
[1] O. Abdel-Wahab,et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. , 2016, Blood.
[2] R. Hills,et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. , 2014, Blood.
[3] J. Szer,et al. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia , 2014, British journal of haematology.
[4] E. Vellenga,et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years , 2014, Leukemia.
[5] R. D'Andrea,et al. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations , 2013, Leukemia.
[6] B. Löwenberg. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. , 2013, Blood.
[7] P. Chevallier,et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. , 2012, Blood.
[8] Y. Min,et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. , 2011, Blood.
[9] T. Naoe,et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.
[10] T. Naoe,et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML 201 Study , 2011 .
[11] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[12] J. Bourhis,et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[14] J. Bennett,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[15] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[16] D. Gilliland,et al. Drug therapy for acute myeloid leukemia. , 2005, Blood.
[17] C. Bloomfield,et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. , 2005, Blood.
[18] J. Szer,et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. , 2005, Blood.
[19] D. Neuberg,et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.
[20] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Murphy,et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. , 2003, The Journal of molecular diagnostics : JMD.
[22] J. Matthews,et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia , 2001, Leukemia.
[23] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[24] J. Reiffers,et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. , 1996, Leukemia.
[25] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[26] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[27] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .
[29] F. Mandelli,et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia , 1991 .
[30] Janice Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .
[31] N. Nissen,et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.